Can anyone articulate the value of the value based care in chronic kidney disease in the era of the #4pillars? Trad #VBC was based on the premise that generic angiotensin blockade was sufficient (false) and underutilized (proven to be wrong by the #UPMC trial that demonstrated that the perceived underutilization was just the ceiling of these therapies). Since most #VBC worked with Medicare Part B (which does not cover drugs), they can not even pay for the #4pillars.
underutilized (proven to be wrong by the #UPMC trial that demonstrated that the perceived underutilization was just the ceiling of these therapies). Since most #VBC worked with Medicare Part B (which does not cover drugs), they can not even pay for the #4pillars.
Can anyone articulate the value of the value based care in chronic kidney disease in the era of the #4pillars? Trad #VBC was based on the premise that generic angiotensin blockade was sufficient (false) and ....
data from #EMPAKIDNEY show that one can deliver material benefits among those who don't tolerate the older therapies. Perhaps I am missing something, but while I see the immense value of programs to deliver #4pillar high value care, I don't see the value to partner with a #VBC.
electronic health record and appointment reminders to track and assist with adherence. Just two of the now generic #4pillars (angiotensin and #flozin) pack more punch than what the #VBC ever promised to deliver. In the angiotensin blocker, intolerant patients ...
If a physician practice could get somehow get their Medicare patients on #angiotensin blockade #flozin #nsMRA and #glp1 (e.g. secondary insurance or coinsurance) why would they partner with a #VBC and share cost savings from the drugs? Just write a script & use the ...
Verbrec ( #VBC ) has released " Verbrec secures over $11m in new contracts " on Wed 21 May at 09:17 AEST #today #Mining #Australia #media #live
https://grafa.com/asset/verbrec-ltd-10605-vbc.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=vbc.asx
Verbrec share price

Verbrec (ASX:VBC) is an asset listed on the ASX, and part of the Industrials sector. Grafa’s asset page shows Verbrec’s share price, chart, trading volume, earn

Grafa
Not all patients need the same care.
Risk stratification helps providers prioritize, personalize, and prevent complications.
Discover the key steps to doing it well in VBC settings ➡️ https://bluebrix.health/blogs/how-to-address-risk-stratification-for-value-based-care
#PopulationHealth #VBC #HealthIT #CareManagement
How to address Risk Stratification for Value-based Care? - blueBriX

Explore how risk stratification transforms healthcare delivery by aligning patients with appropriate care initiatives, ensuring proactive interventions for high-risk populations.

blueBriX
Verbrec ( #VBC ) has released " Verbrec signs StacksOn Reseller Agreement with Datamine " on Tue 25 Mar at 09:18 AEST #today #Mining #Australia #media #live
https://grafa.com/asset/verbrec-ltd-10605-vbc.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=vbc.asx
Verbrec share price

Verbrec (ASX:VBC) is an asset listed on the ASX, and part of the Industrials sector. Grafa’s asset page shows Verbrec’s share price, chart, trading volume, earn

Grafa